Here are five key points:
1. In the Federal Trade Commission filing, Stryker pushed the anti-monopoly waiting period to Nov. 16.
2. Shareholders are scheduled to vote on the deal Nov. 7. Recently, a few K2M shareholders filed to stop the acquisition, stating the deal did not properly value K2M.
3. In the lawsuit to stop the acquisition, K2M shareholders argue the company’s management did not disclose financial projections from its financial advisor. Arguments are scheduled for Oct 29.
4. Stryker said the company intends to “vigorously defend” against the lawsuit from K2M shareholders, according to the Oct. 17 filing.
5. The $1.4 billion deal is a 27 percent premium over K2M’s average closing price. Stryker expects the deal to close during the fourth quarter.
More articles on devices and implants:
OrthoPediatrics earns FDA clearance for small stature scoliosis system: 4 details
What to expect from Paradigm Spine in the future: 5 Qs with CEO Marc Viscogliosi
Simplify Medical adds VP of general counsel: 4 key points
